InforSense has released the InforSense VisualSense and Document Explorer, two web-based solutions for the company's flagship analytics platform that help users quickly and easily navigate through large amounts of complex data.
InforSense has released the InforSense Virtual Machine (IVM), which is a standalone, lightweight workflow execution engine that can be embedded into third-party applications that run on a wide variety of platforms including workstations, servers, scientific instrumentation, embedded devices or mobile devices.
Richard Solari, former director of business intelligence at Oracle, has joined InforSense as vice president of analytic solutions. Solari will be responsible for the companys overall expansion into new markets.
InforSense has received an investment of $10m, led by two of its largest investors, Fleming Family & Partners (FF&P) and Imperial Innovations Group.
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
